Biosimilars show real potential to disrupt the pharma market with launch in Europe
The advancement of biosimilars moves another step forward today with the launch of versions of a rheumatoid arthritis and Crohn’s disease drug to European markets. The products, which come from South Korean firm Celltrion and its partners Hospira and Mundipharma, will be in competition with the Johnson & Johnson and Merck & Co. drug Remicade. […]